MoA studies of molecules derived from TB bacteria for the treatment of asthma

Peptinnovate have discovered that proteins derived from mycobacterium tuberculosis (mTB) unexpectedly act as potent anti-inflammatory agents both in vivo (animal) and in vitro (human and animal), via an unknown mechanism of action. Peptide fragments of the mTB protein have been successfully synthesised and shown to have equivalent or augmented activity in these systems.
This project focuses on the use of these proprietary compounds to probe their mechanism of action for use in steroid resistant asthma supporting Peptinnovate's (SME) growth strategy. We will use innovative in vitro and in vivo techniques on human immune cells and in animal models. The resulting mechanistic understanding will allow Peptinnovate to be potentially the first to develop new medicines based on the unique properties of mTB proteins, making Peptinnovate an attractive licence partner, increasing UK investment, and providing therapeutic options to the patients.